Acquisition

July 23, 2026 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company Code No. 524804 Dear Sir / Madam, Sub: Acquisition of majority ownership control in A1 Biochem Labs (India) Private Limited, India and A1 Biochem Labs LLC, USA – Reg., Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that: Apitoria Pharma Private Limited ("Apitoria"), a wholly owned subsidiary of Aurobindo Pharma Limited (the "Company"), at its meeting held today, i.e., July 23, 2026, has approved the acquisition of 80% ownership in the Contract Research Services business of A1 Biochem Group, at an enterprise value of USD 17 million, on a debt-free and cash-free basis. A1 Biochem Group is a Contract Research Organization (CRO) providing high-quality chemistry services to pharmaceutical companies, biotechs, and academic institutions, primarily in the USA. Its services include custom synthesis, medicinal chemistry, route scouting, analytical development, and rapid process scale- up services. A1 Biochem Group comprises: (a) A1 Biochem Labs (India) Private Limited, India; (b) the business of A1 Biochem Research (India) Private Limited, India; and (c) A1 Biochem Labs LLC, USA. Upon completion of the acquisition, Apitoria will hold 80% ownership in A1 Biochem Labs (India) Private Limited, India, with the existing promoter of A1 Biochem Group retaining the remaining 20% ownership. A1 Biochem Labs (India) Private Limited, India will acquire 100% ownership of A1 Biochem Labs LLC, USA and A1 Biochem Labs (India) Private Limited, India will acquire the business of A1 Biochem Research (India) Private Limited, India. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure. This is for your information and record. Thanking you, Yours faithfully, For AUROBINDO PHARMA LIMITED B. Adi Reddy Company Secretary Encl.: Annexure Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com Annexure Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 a) Name of the target entity, details in brief such as i) Name of the Target Entities: size, turnover etc.; • Acquisition of 80% stake in A1 Biochem Labs (India) Private Limited, India; • A1 Biochem Labs (India) Private Limited, India to enter into Business Transfer Agreement with A1 Biochem Research (India) Private Limited, India; for acquiring CRO business and • Acquisition of 100% stake of A1 Biochem Labs LLC, USA by A1 Biochem Labs (India) Private Limited, India (prior to closing, A1 Biochem Labs LLC, USA undergoes a re-organization). ii) Details of the Target Business: The Target Business comprises of CRO business that provides high-quality chemistry services to pharmaceutical companies, biotechs, and academic institutions providing custom synthesis, medicinal chemistry, route scouting, analytical development, and rapid process scale-up services A1 Biochem Group generated turnover of INR 1,024.42 Mn in FY2025-26 with an EBITDA of INR 465.46 Mn. A1 Biochem Group comprises of two scientific laboratories located in Wilmington, North Carolina, USA, and Hyderabad, India. The group is led by Dr. Rajendra Gadikota who has 25+ years’ experience in this business and shall continue to be with the group after the acquisition. The group currently has 50+ fume hoods and 90+ scientists in the Target Business. b) Whether the acquisition would fall within related The acquisition does not fall under related party party transaction(s) and whether the promoter / transaction. promoter group/ group companies have any interest in the entity being acquired? If yes, nature The promoter / promoter group/ group companies do of interest and details thereof and whether the not have any interest in the Target Entities or Target same is done at “arms-length”; Business being acquired. c) Industry to which the business of the target Pharmaceuticals industry. entity being acquired belongs; d) Name of acquirer Apitoria Pharma Private Limited, India. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com e) Relationship of acquirer with the listed entity Apitoria Pharma Private Limited is a wholly owned subsidiary of Aurobindo Pharma Limited. f) Objects and effects of acquisition (including but The transaction aligns with the Company’s strategic not limited to, disclosure of reasons for acquisition objective of expanding its presence in the life cycle of of target entity, if its business is outside the main Active Pharmaceutical Ingredients (API) business. line of business of the listed entity); Apitoria is currently engaged in large-scale, regulatory- compliant API manufacturing. Through this acquisition of front-end research and development capability, the Company will be able to create a dedicated Contract Research, Development and Manufacturing (CRDMO) platform. It will expand the portfolio of the Company facilitating full service, longer life cycle engagement with the customers. This transaction is complementary to the current API manufacturing business of Apitoria. Further, transaction will grant access to an existing CRO platform with 50+ client base and completed 800+ projects in USA and create an integrated CRDMO platform complementing the existing manufacturing business of Apitoria. The acquisition will be subject to completion of the conditions prescribed under the Definitive Agreements. g) Brief details of any governmental or regulatory Transaction is subject to customary approvals. approvals required for the acquisition; h) Indicative time period for completion of the 90 - 120 days. acquisition; i) Nature of consideration - whether cash Cash consideration. consideration or share swap and details of the same e) Cost of acquisition or the price at which the The CRO Business of A1 Biochem Group will be shares/ business are acquired; acquired at an enterprise value of USD 17 Million on a debt free and cash free basis. The Company will invest USD 13.6 Million for its 80% ownership in the A1 Biochem Group, subject to adjustments as on the closing of transaction. Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044. Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038, Telangana., India. Tel: +91 40 2373 6370/ 2374 7340 Fax: +91 40 2374 1080 / 2374 6833 Email: info@aurobindo.com Website: www.aurobindo.com k) Percentage of shareholding / control acquired Apitoria will acquire 80% ownership in A1 Biochem and / or number of shares acquired; Group whereby on close of the transaction, Apitoria will hold 80% ownership in A1 Biochem Labs (India) Private Limited, India; and A1 Biochem Labs (India) Private Limited, India, will hold 100% ownership of A1 Biochem Lab [Showing first 8,000 characters — download PDF for full document]